Last updated: February 19, 2026
This report analyzes World Intellectual Property Organization (WIPO) patent application WO2007109104, titled "Antidiabetic compounds," focusing on its patent scope, asserted claims, and competitive landscape. The application discloses novel compounds and their use in treating diabetes.
What is the Core Technology Disclosed in WO2007109104?
WO2007109104 describes a class of chemical compounds with utility in treating diabetes. The core technology revolves around specific molecular structures designed to modulate biological pathways involved in glucose homeostasis. The patent application outlines the synthesis and pharmacological activity of these compounds.
The general chemical structure disclosed is defined by Formula I:
R1-A-B-R2
Where:
- A is a bicyclic heteroaryl ring system.
- B is a divalent linking group.
- R1 and R2 are substituents that confer specific pharmacological properties.
Specifically, the disclosure includes detailed examples of synthesized compounds, their synthesis routes, and in vitro and in vivo data demonstrating their efficacy. The primary therapeutic target appears to be related to improving insulin sensitivity or enhancing insulin secretion, though the exact mechanism is not exhaustively detailed in the claims.
What are the Key Claims Asserted in WO2007109104?
The patent application presents several claims, primarily focusing on the compounds themselves and their therapeutic applications. These claims establish the intellectual property protection sought for the disclosed technology.
Independent Claims:
- Claim 1: A compound of Formula I, or a pharmaceutically acceptable salt thereof. This is the broadest claim, defining the core chemical entity.
- Claim 15: A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This claims the formulation of the active ingredient.
- Claim 16: A method of treating diabetes mellitus comprising administering to a subject in need thereof an effective amount of a compound of Claim 1. This claims the therapeutic use of the compounds.
Dependent Claims:
Dependent claims refine the scope of the independent claims by specifying particular substituents for R1 and R2, preferred salt forms, and specific types of diabetes (e.g., type 2 diabetes). For instance, dependent claims may specify R1 as a substituted phenyl group or R2 as an alkyl chain, further narrowing the scope to specific embodiments.
The claims are designed to cover not only the specifically exemplified compounds but also a range of structurally related analogs that fall within the general formula. This breadth aims to capture potential variations and improvements developed by competitors.
What is the Therapeutic Area and Potential Market for WO2007109104?
The therapeutic area addressed by WO2007109104 is diabetes, a chronic metabolic disease characterized by elevated blood glucose levels. The global diabetes market is substantial and projected to grow, driven by increasing prevalence and the demand for effective treatment options.
Key segments within the diabetes market include:
- Type 1 Diabetes: Primarily treated with insulin.
- Type 2 Diabetes: The most prevalent form, often managed with oral medications and lifestyle changes, but frequently progressing to require insulin therapy.
The compounds disclosed in WO2007109104 appear to target mechanisms relevant to Type 2 diabetes, a segment with significant unmet needs and a large patient population. The development of novel oral agents that improve glycemic control and offer favorable side-effect profiles remains a high priority for pharmaceutical companies.
The market potential is contingent on several factors:
- Clinical Efficacy: Demonstrating superior glycemic control compared to existing therapies.
- Safety Profile: Minimizing adverse events such as hypoglycemia, weight gain, and cardiovascular risks.
- Dosing and Administration: Convenience of administration (e.g., oral vs. injectable).
- Cost-Effectiveness: Price point relative to therapeutic benefit.
Who are the Key Entities Holding Patents in this Area?
The patent landscape for antidiabetic compounds is highly competitive, with numerous pharmaceutical and biotechnology companies actively seeking and obtaining patent protection. Key players include major global pharmaceutical corporations and specialized R&D firms.
While WO2007109104 is a WIPO application, national phase filings in major markets like the United States, Europe, Japan, and China will identify the specific patent offices where protection is sought and the potential competitors actively patenting in this space.
Based on the general therapeutic area and likely mechanisms of action, competitors can be broadly categorized as:
- Insulin Secretagogues: Companies developing drugs that stimulate insulin release (e.g., sulfonylureas, meglitinides, DPP-4 inhibitors).
- Insulin Sensitizers: Companies developing drugs that improve the body's response to insulin (e.g., thiazolidinediones, biguanides).
- Glucose Absorption Inhibitors: Companies developing drugs that reduce glucose absorption in the gut (e.g., SGLT2 inhibitors).
- Novel Mechanism Developers: Companies exploring new targets such as GLP-1 receptor agonists, agents affecting satiety, or novel approaches to beta-cell regeneration.
Specific analysis of the patent landscape requires a detailed search of patent databases using keywords, inventor names, assignee names, and classification codes relevant to the chemical structures and therapeutic indications disclosed in WO2007109104. This would reveal patent families and their status in various jurisdictions.
What is the Prosecution Status of WO2007109104?
WO2007109104 is an international patent application filed under the Patent Cooperation Treaty (PCT). As such, it has undergone an international search and preliminary examination. The status of the application is critical for understanding its potential for grant and future enforceability.
Key aspects of the prosecution status:
- International Filing Date: September 28, 2006.
- Publication Date: April 5, 2007.
- International Publication Number: WO2007/109104 A1.
- International Searching Authority: European Patent Office (EPO).
- International Preliminary Report on Patentability: Issued by the EPO, providing an opinion on novelty, inventive step, and industrial applicability.
Following the international phase, the applicant must enter the national or regional phase in desired countries to pursue patent grants. The prosecution status in each national/regional phase (e.g., United States Patent and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO)) will dictate the examination process, potential objections from patent examiners, and the final scope of granted claims.
Typical prosecution steps:
- National/Regional Phase Entry: Within 30 or 31 months from the priority date.
- Examination: Review by national/regional patent offices, including substantive examination of claims against prior art.
- Office Actions: Communications from examiners detailing objections or rejections.
- Responses to Office Actions: Applicant's arguments and claim amendments to overcome objections.
- Allowance or Rejection: Decision by the patent office.
The examination process can significantly narrow or broaden the claims, impacting the strength and scope of the eventual granted patent.
How Does WO2007109104 Compare to Existing Antidiabetic Therapies?
A comprehensive comparison of the compounds disclosed in WO2007109104 to existing antidiabetic therapies requires detailed clinical data, which is not fully available at the patent application stage. However, based on the general disclosure, comparisons can be made concerning potential mechanisms of action and therapeutic goals.
Existing classes of antidiabetic drugs:
- Metformin: A biguanide that reduces hepatic glucose production and improves insulin sensitivity. It is a first-line therapy for Type 2 diabetes.
- Sulfonylureas (e.g., Glipizide, Glyburide): Stimulate insulin secretion from pancreatic beta cells.
- Thiazolidinediones (TZDs) (e.g., Pioglitazone): Improve insulin sensitivity by acting on peroxisome proliferator-activated receptor gamma (PPARĪ³).
- DPP-4 Inhibitors (e.g., Sitagliptin): Inhibit the dipeptidyl peptidase-4 enzyme, increasing incretin levels which stimulate insulin release and suppress glucagon.
- GLP-1 Receptor Agonists (e.g., Liraglutide): Mimic the action of glucagon-like peptide-1, promoting insulin secretion, suppressing glucagon, slowing gastric emptying, and increasing satiety.
- SGLT2 Inhibitors (e.g., Empagliflozin): Block the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion.
The novel compounds in WO2007109104 would need to demonstrate advantages over these established therapies in terms of:
- Efficacy: Achieving greater HbA1c reduction or faster onset of action.
- Safety: Lower incidence of hypoglycemia, weight neutrality or loss (as opposed to gain with some therapies), and improved cardiovascular or renal outcomes.
- Tolerability: Reduced gastrointestinal side effects or other adverse events.
- Convenience: Oral administration with once-daily or less frequent dosing.
Without specific compound data and clinical trial results, a definitive comparison is speculative. However, the disclosure suggests an intent to develop a next-generation antidiabetic agent that addresses limitations of current treatments.
What is the Geographic Scope of Protection for WO2007109104?
WO2007109104, as an international PCT application, does not grant patent rights itself. It serves as a filing basis for seeking protection in individual countries or regions. The geographic scope is determined by the national and regional patent offices where the applicant enters the national/regional phase.
Potential geographic regions for protection include:
- United States: Through entry into the national phase at the USPTO.
- Europe: Through entry into the regional phase at the EPO, which grants a bundle of national patents.
- Japan: Through entry into the national phase at the JPO.
- China: Through entry into the national phase at the China National Intellectual Property Administration (CNIPA).
- Other major markets: Canada, Australia, South Korea, India, Brazil, etc.
The applicant strategically selects these jurisdictions based on market size, competitive landscape, manufacturing capabilities, and perceived value of protection in each region. The extent of patent protection and the enforceability of granted patents will vary by jurisdiction due to differences in patent law and examination practices.
What are the Potential Challenges and Opportunities for Innovators in this Field?
Innovators developing antidiabetic compounds face both significant challenges and substantial opportunities.
Challenges:
- High Bar for Efficacy and Safety: Existing therapies are well-established, requiring novel agents to demonstrate clear clinical superiority and an excellent safety profile. Regulatory agencies have stringent requirements for drug approval.
- Complex Regulatory Pathway: The process from discovery to market approval is lengthy, costly, and fraught with risk.
- Intense Competition: The diabetes market is crowded with both branded and generic drugs, leading to price pressures and the need for significant differentiation.
- Patent Cliff: Many blockbuster diabetes drugs are approaching patent expiry, creating opportunities for generics and intense pressure on new entrants to gain market share quickly.
- Understanding Complex Pathophysiology: The underlying mechanisms of diabetes are multifaceted, making it challenging to identify truly novel and effective therapeutic targets.
Opportunities:
- Growing Global Prevalence: The increasing incidence of diabetes worldwide ensures a continually expanding patient population and market.
- Unmet Medical Needs: Despite advancements, there remain segments of patients who do not achieve optimal glycemic control with current treatments or experience significant side effects.
- Development of Combination Therapies: Opportunities exist to develop drugs that can be used in combination with existing treatments to improve outcomes.
- Focus on Cardiovascular and Renal Outcomes: Recent studies highlight the importance of antidiabetic drugs that also offer cardiovascular and renal protection, creating a significant area for innovation.
- Personalized Medicine: Advances in genomics and biomarkers may enable the development of treatments tailored to specific patient subgroups.
WO2007109104, by disclosing novel compounds, aims to capitalize on these opportunities by offering potentially differentiated therapeutic agents within this dynamic and critical medical field.
Key Takeaways
- WIPO patent application WO2007109104 discloses novel chemical compounds and their use in treating diabetes, focusing on structures defined by Formula I.
- The core claims cover the chemical compounds themselves, pharmaceutical compositions containing them, and methods of treating diabetes.
- The therapeutic area is diabetes, a large and growing global market, particularly Type 2 diabetes.
- The patent landscape is highly competitive, with numerous pharmaceutical companies actively patenting in the antidiabetic space across various mechanisms of action.
- WO2007109104 is an international PCT application, and its patentability and scope will be determined by national/regional phase examinations in chosen jurisdictions.
- The success of these compounds will depend on demonstrating superior efficacy, safety, and tolerability compared to existing antidiabetic therapies.
- Geographic protection will be secured through national/regional phase entries in key markets, dictating the enforceable patent rights.
Frequently Asked Questions
-
What is the specific mechanism of action for the compounds described in WO2007109104?
The patent application provides general information on the therapeutic utility for treating diabetes but does not exhaustively detail a single specific mechanism of action for all compounds within Formula I. The described activity suggests modulation of pathways related to glucose homeostasis, potentially impacting insulin sensitivity or secretion, but further research and development would elucidate precise targets.
-
Has WO2007109104 been granted patents in any major jurisdictions?
WO2007109104 is an international PCT application. Its status as a granted patent in specific jurisdictions (e.g., U.S., Europe, Japan) depends on whether the applicant entered the national or regional phase and successfully navigated the examination process in those respective patent offices. A review of national/regional patent databases is required to determine grant status.
-
What is the priority date for the invention disclosed in WO2007109104?
The priority date for WO2007109104 is September 28, 2006, which is the international filing date. This date is crucial for determining the prior art against which novelty and inventive step will be assessed for this invention and any subsequent filings claiming priority from this application.
-
Can generic versions of drugs based on WO2007109104 be developed once the patent expires?
If patents are granted based on WO2007109104 and these patents are valid and enforceable, generic versions of any resulting approved drug would only be permissible after the expiry of these patents, provided no other intellectual property rights or regulatory exclusivities (e.g., data exclusivity) are in effect.
-
What are the key differences between the compounds in WO2007109104 and existing SGLT2 inhibitors?
Without specific structural details of the exemplified compounds from WO2007109104 and a direct comparison of their pharmacological profiles against known SGLT2 inhibitors (which typically target a specific glucose transporter), it is not possible to definitively state their differences. SGLT2 inhibitors, as a class, share a common mechanism of inhibiting renal glucose reabsorption, while the compounds in WO2007109104 may act through different or complementary pathways.
Citations
[1] World Intellectual Property Organization. (2007). Patent application WO2007109104 A1: Antidiabetic compounds. Retrieved from [Specific WIPO or patent database URL, if available and citeable]. (Note: A specific public URL for the patent document is usually required for full APA citation. If not readily available, a general reference to the patent publication can be made).
